公开(公告)号：US20240100142A1

公开(公告)日：2024-03-28

申请号：US18315781

申请日：2023-05-11

Applicant: CureVac SE

Inventor： Tilmann ROOS ,  Martin KUNZE ,  Benyamin YAZDAN PANAH ,  Salih YILMAZ ,  Markus CONZELMANN

IPC: A61K39/12 ,  A61P21/00 ,  A61P31/00 ,  A61P39/00 ,  C07K14/005 ,  C12N15/10 ,  C12Q1/6844 ,  C40B40/02 ,  C40B40/08

CPC classification number: A61K39/12 ,  A61P21/00 ,  A61P31/00 ,  A61P39/00 ,  C07K14/005 ,  C12N15/1024 ,  C12Q1/6844 ,  C40B40/02 ,  C40B40/08 ,  A61K2039/53

Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.

公开(公告)号：US20240150386A1

公开(公告)日：2024-05-09

申请号：US18320598

申请日：2023-05-19

Applicant: CureVac SE

Inventor： Stefan HEINZ ,  Tilmann ROOS ,  Dominik VAHRENHORST ,  Markus CONZELMANN

IPC: C07H1/06 ,  A61K31/713

CPC classification number: C07H1/06 ,  A61K31/713

Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine. Moreover, the present invention concerns a method for providing an adapted RNA sequence or an adapted RNA mixture.

公开(公告)号：US20250099614A1

公开(公告)日：2025-03-27

申请号：US18833889

申请日：2023-01-27

Applicant: CureVac SE ,  The Schepens Eye Research Institute, Inc.

Inventor： Joanna REJMAN ,  Tim SONNTAG ,  Markus CONZELMANN ,  Joseph ARBOLEDA-VELASQUEZ ,  Leo A. KIM

IPC: A61K48/00 ,  A61K9/127 ,  A61P27/02 ,  C07K14/47

Abstract: The present invention is inter alia directed to artificial nucleic acid constructs, preferably RNA, comprising at least one coding sequence encoding at least one transcription factor inhibitor for reducing or inhibiting the activity of a target transcription factor in a cell. A preferred transcription factor inhibitor according to the invention is a Runt-related transcription factor (RUNX) inhibitor, for example a RUNX trap comprising at least one amino acid sequence for binding a RUNX transcription factor and at least one amino acid sequence for capturing or trapping RUNX. Further provided are pharmaceutical compositions comprising the artificial nucleic acid, preferably formulated in polyethylene glycol/peptide polymers, polymeric carriers, or lipid-based carriers. Also provided are methods of treating or preventing disorders, diseases, or conditions, and medical uses.

公开(公告)号：US20230227881A1

公开(公告)日：2023-07-20

申请号：US18154437

申请日：2023-01-13

Applicant: CureVac SE

Inventor： Tilmann ROOS ,  Benyamin YAZDAN PANAH ,  Markus CONZELMANN ,  Andreas THESS ,  Dominik BUOB ,  Martin KUNZE ,  Veronika WAGNER

IPC: C12P19/34 ,  C12N9/10 ,  C12N9/16 ,  C12N9/12 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

CPC classification number: C12P19/34 ,  C12N9/1007 ,  C12Y201/01057 ,  C12Y201/01056 ,  C12Y301/03033 ,  C12N9/16 ,  C12Y207/0705 ,  C12N9/1241 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2′-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2′-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5′-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5′-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2′-O-methyltransferase.